Clinical use of FLT3 inhibitors in acute myeloid leukemia.

摘要: Acute myeloid leukemia (AML) is a highly heterogeneous disease. Mutation with internal tandem duplication of fms-like tyrosine kinase-3 (FLT3-ITD) one the two most common driver mutations and presence FLT3-ITD delivers poor prognosis. A number ongoing clinical efforts are focused on FLT3 inhibitor use to improve outcomes this otherwise difficult leukemia. Midostaurin has been shown in FLT3-mutated AML frontline setting. Several inhibitors, especially second-generation agents, have clinically meaningful activity relapsed or refractory patients not amenable intensive therapy. In article, we briefly review biology physiological state its role leukemogenesis. We present detailed current evidence inhibitors their induction, treatment disease, maintenance